HB6089 would establish a National Biopharmaceutical Center of Excellence within the National Institute of Standards and Technology (NIST) to advance biopharmaceutical manufacturing in the United States. It would fund construction, research, and workforce training, and set criteria for selecting an entity to operate the center.
The bill also requires annual reporting to Congress, establishes intellectual property guidelines, and authorizes $120 million for FY2026 to support these activities. The aim is to strengthen domestic capability, reduce supply chain risk, and accelerate the deployment of innovative manufacturing tech.
At a Glance
What It Does
The bill creates the National Biopharmaceutical Center of Excellence within the NIST Act, awarding a grant or other transaction to an eligible entity to establish and operate the Center. It sets objectives around flexible manufacturing tech, quality by design, workforce training, and cross-sector collaboration.
Who It Affects
Eligible applicants include public-private partnerships, institutions of higher education, or consortia (not Federal entities). It will affect universities, biotech manufacturers (including SMEs), industry partners, and workforce training providers partnering with government and academia.
Why It Matters
By coordinating federal investment in biopharmaceutical manufacturing, the bill seeks to reduce dependence on foreign supply chains, accelerate scale-up from lab to production, and strengthen national health and economic security through advanced manufacturing capabilities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Biomanufacturing Excellence Act would amend the National Institute of Standards and Technology Act to insert a new Section 36, creating the National Biopharmaceutical Center of Excellence. The Director would award a grant or other transaction to an eligible entity—public-private partnerships, institutions of higher education, or consortia—with the aim of establishing and operating the Center of Excellence.
The Center’s objectives include advancing biopharmaceutical manufacturing technologies, improving upstream and downstream processes, standardizing manufacturing practices, and reducing supply bottlenecks to improve domestic self-sufficiency.
The Five Things You Need to Know
The bill creates the Center of Excellence within the NIST framework and designates a Director to oversee funding and operations.
Funding authorization of $120,000,000 is provided for fiscal year 2026 to construct facilities, fund research, and support workforce training.
Eligibility is limited to public-private partnerships, institutions of higher education, or consortia; Federal entities are ineligible.
The Center focuses on flexible manufacturing technologies, quality by design, and standardized chemistry, manufacturing, and controls to streamline regulation and deployment.
Annual reporting to Congress is required, including progress, partnerships, and operational findings, with IP guidelines established before operations begin.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Congress redesignates and inserts new Center framework into NIST Act
The bill amends the National Institute of Standards and Technology Act by redesignating section 36 as section 37 and inserting a new Section 36 that establishes the National Biopharmaceutical Center of Excellence. This creates a formal, government-supported mechanism to fund and govern a center dedicated to advancing biopharmaceutical manufacturing, with explicit objectives and funding parameters.
Establishment and objectives of the Center
This subsection sets out the establishment of the Center of Excellence and enumerates its core objectives. It authorizes the Director to fund an eligible entity to operate the Center and defines the aims: developing flexible biopharmaceutical manufacturing technologies, improving manufacturing processes, reducing bottlenecks, advancing good manufacturing practices, workforce training, and collaboration with educational, public, and private partners to sustain U.S. leadership in biotechnology manufacturing.
Application, eligibility, and selection
Not later than 180 days after enactment, the Director must solicit applications and select one eligible entity—public-private partnerships, institutions of higher education, or consortia—to establish the Center. Applications must demonstrate prior relevant work, plans to advance national security-relevant manufacturing, incorporation of GMP and quality by design, workforce training, and partnerships. The Director will evaluate proposals based on impact, regional coverage, leveraging of existing initiatives, timing, co-investment, and other relevant criteria.
Annual reporting
The statute requires an initial report within one year of awarding the center, a progress report within one year of operations beginning, and a final report within five years. Each report must describe facilities, partnerships, activities, findings, and other relevant information, and must be publicly accessible online as part of a government biotechnology portal.
Intellectual property guidelines
Before operations begin, the Center must establish IP guidelines in consultation with similar existing institutes (e.g., Manufacturing USA). The guidelines will govern research conducted at the Center and collaborations, balancing innovation with appropriate protection and dissemination of technology.
Authorization of appropriations
The bill authorizes $120,000,000 for FY2026 to carry out Section 36, including construction, research, and workforce activities tied to the Center of Excellence.
Definitions
Key terms are defined: biomanufacturing (application of biotechnology to manufacturing), biopharmaceutical (drugs produced using living cells or organisms), biotechnology (application of science/engineering to living systems), Executive Agency, and Institution of Higher Education (as defined in current U.S. law). These definitions anchor the scope of activities and participants.
This bill is one of many.
Codify tracks hundreds of bills on Technology across all five countries.
Explore Technology in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Public-private partnerships that would host and operate the Center gain access to federal funding, facilities, and collaboration networks to accelerate biopharmaceutical manufacturing.
- Institutions of higher education and consortia partnering with industry can expand research agendas and workforce training programs with federal support.
- Small and medium biopharmaceutical manufacturers benefit from access to scalable manufacturing technologies, best practices, and potential inclusion in demonstration projects.
- Educational and community partners involved in workforce development gain resources for training programs aligned with industry needs.
- Federal, state, and local governments benefit from a more resilient, domestically produced biotech supply chain and improved national security in health and economic domains.
Who Bears the Cost
- Federal government bears the direct cost of appropriations to fund the Center (and related administrative costs).
- Taxpayers are the ultimate financiers of the program through federal appropriations and potential future budgetary commitments.
- Participating entities may be required to provide co-investment or in-kind contributions to leverage federal funds, creating funding obligations for universities and private partners.
- Regulatory and oversight agencies may incur additional administration and monitoring costs associated with GMP standardization, IP governance, and reporting.
- Local communities hosting Center facilities may face upfront infrastructure or zoning costs as facilities are constructed or expanded.
Key Issues
The Core Tension
The central dilemma is how to maximize domestic biomanufacturing capability through a federally funded Center while ensuring flexible collaboration, timely deployment of new technologies, and robust IP protections that do not impede innovation or competitive advantage.
The bill promises transformative capability for U.S. biopharmaceutical manufacturing, but it also raises policy tensions. Substantial federal funding for a single National Center of Excellence could crowd out parallel efforts or duplicate existing programs unless the statute’s authorizing language emphasizes coordination with other initiatives.
The IP guidelines are intended to balance openness with protection of innovations, yet they pose a risk of slowing deployment if procedures are overly restrictive or misaligned with evolving manufacturing technologies. Finally, the bill links national security objectives to manufacturing policy, which might privilege projects with perceived security benefits over broader public health needs, creating questions about allocation of federal and state resources and geographic distribution of centers.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.